Is Generate Biomedicines, Inc. (GENB) a Buy, Sell, or Hold?
Generate Biomedicines, Inc.
NASDAQ:GENB
$14.21 USD
-$0.07 (-0.49%)
- Volume
- 393.65K
- Average Volume
- 786.67K
- Market Capitalization
- $1.82B
- P/E Ratio
- -2.85
- Dividend Yield
- 0.00%
- Price Target
- $23.50
- Year High
- $18.18
- Year Low
- $11.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.85
| Source | Headline |
|---|---|
|
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
The chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines. Nvidia CEO Jensen Huang sees a powerful intersection between health and AI. fool.com - 2026-07-11 11:37:00 |
|
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
Newly Constructed Phase 2 now 100% Leased Further Solidifies Innovation Park as Boston's Premier Advanced Manufacturing Destination BOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100% leased. prnewswire.com - 2026-06-22 08:00:00 |
|
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs. fool.com - 2026-05-31 16:17:57 |
|
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
SOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. prnewswire.com - 2026-05-28 16:20:00 |
|
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted progress across its clinical portfolio. prnewswire.com - 2026-05-07 06:16:00 |
